BRPI0514532A - composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo - Google Patents

composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo

Info

Publication number
BRPI0514532A
BRPI0514532A BRPI0514532-5A BRPI0514532A BRPI0514532A BR PI0514532 A BRPI0514532 A BR PI0514532A BR PI0514532 A BRPI0514532 A BR PI0514532A BR PI0514532 A BRPI0514532 A BR PI0514532A
Authority
BR
Brazil
Prior art keywords
gastric
pharmaceutical composition
active ingredient
permanently
tablet containing
Prior art date
Application number
BRPI0514532-5A
Other languages
English (en)
Inventor
Gerard Alaux
Estelle Chouin
Nathalie Dufresne-Arokiassamy
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514532(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0514532A publication Critical patent/BRPI0514532A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIçãO FARMACêUTICA SOB A FORMA DE COMPRIMIDO COM PERMANêNCIA GáSTRICA, CONTENDO UM PRINCìPIO ATIVO. A presente invenção refere-se a composição farmacêutica sob a forma de um comprimido matricial de permanência gástrica, compreendendo um principio ativo, caracterizada pelo fato de, em contato com um meio representativo do suco gástrico, ela aumentar, após quinze minutos em volume, de uma taxa de intumescência de pelo menos 200%.
BRPI0514532-5A 2004-08-19 2005-08-17 composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo BRPI0514532A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408986A FR2874325B1 (fr) 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
PCT/FR2005/002092 WO2006021692A1 (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif

Publications (1)

Publication Number Publication Date
BRPI0514532A true BRPI0514532A (pt) 2008-06-17

Family

ID=34950702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514532-5A BRPI0514532A (pt) 2004-08-19 2005-08-17 composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo

Country Status (22)

Country Link
US (1) US20070190140A1 (pt)
EP (1) EP1781295A1 (pt)
JP (1) JP5048492B2 (pt)
KR (1) KR20070046124A (pt)
CN (1) CN101022808B (pt)
AR (1) AR050696A1 (pt)
AU (1) AU2005276307B2 (pt)
BR (1) BRPI0514532A (pt)
CA (1) CA2577361C (pt)
EA (1) EA012981B1 (pt)
FR (1) FR2874325B1 (pt)
IL (1) IL181150A0 (pt)
MA (1) MA28862B1 (pt)
MX (1) MX2007001957A (pt)
MY (1) MY145832A (pt)
NO (1) NO20071315L (pt)
NZ (1) NZ553673A (pt)
PE (1) PE20060639A1 (pt)
TW (1) TWI357329B (pt)
UY (1) UY29073A1 (pt)
WO (1) WO2006021692A1 (pt)
ZA (1) ZA200701443B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
JP2008280251A (ja) * 2007-05-08 2008-11-20 Shin Etsu Chem Co Ltd 多層錠及びその製造方法
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
ES2600894T3 (es) * 2010-02-22 2017-02-13 Daiichi Sankyo Company, Limited Preparación sólida de liberación sostenida para uso oral
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
RU2545812C1 (ru) * 2014-02-24 2015-04-10 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона
US10245034B2 (en) * 2015-08-31 2019-04-02 Ethicon Llc Inducing tissue adhesions using surgical adjuncts and medicants
US10569071B2 (en) 2015-08-31 2020-02-25 Ethicon Llc Medicant eluting adjuncts and methods of using medicant eluting adjuncts
CN112426519A (zh) * 2020-11-29 2021-03-02 长沙晶易医药科技有限公司 一种含乙醇脱氢酶和乙醛脱氢酶的胃滞留缓释制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
KR100364328B1 (ko) * 1996-08-29 2002-12-26 사노피-신델라보 알푸조신 염산염의 제어방출 정제
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
HUP0301465A3 (en) * 2000-06-23 2006-07-28 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881424B1 (en) * 2000-09-05 2005-04-19 Mionix Corporation Highly acidic metalated organic acid
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors

Also Published As

Publication number Publication date
AR050696A1 (es) 2006-11-15
FR2874325A1 (fr) 2006-02-24
JP2008509973A (ja) 2008-04-03
US20070190140A1 (en) 2007-08-16
EP1781295A1 (fr) 2007-05-09
TW200618802A (en) 2006-06-16
FR2874325B1 (fr) 2006-10-20
ZA200701443B (en) 2008-05-25
HK1112575A1 (en) 2008-09-12
WO2006021692A8 (fr) 2007-04-12
NO20071315L (no) 2007-03-09
NZ553673A (en) 2010-10-29
CN101022808A (zh) 2007-08-22
CN101022808B (zh) 2013-05-29
JP5048492B2 (ja) 2012-10-17
CA2577361A1 (fr) 2006-03-02
AU2005276307B2 (en) 2011-02-24
MX2007001957A (es) 2007-04-25
MY145832A (en) 2012-04-30
WO2006021692A1 (fr) 2006-03-02
EA012981B1 (ru) 2010-02-26
EA200700217A1 (ru) 2007-08-31
TWI357329B (en) 2012-02-01
KR20070046124A (ko) 2007-05-02
CA2577361C (fr) 2013-10-01
MA28862B1 (fr) 2007-09-03
UY29073A1 (es) 2006-03-31
AU2005276307A1 (en) 2006-03-02
IL181150A0 (en) 2007-07-04
PE20060639A1 (es) 2006-07-20

Similar Documents

Publication Publication Date Title
BRPI0413361B8 (pt) comprimido seguro contra abuso termo-moldado por extrusão sem descoramento
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
JP2009516717A5 (pt)
BRPI0514532A (pt) composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo
CL2008000304A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.
IL177977A0 (en) Non-aromatic, monocyclic, heterocyclic compounds and pharmaceutical compositions containing the same
BRPI0816587A2 (pt) Composição de pellet de ácido lipóico, uso de uma composição e unidade de dosagem
EP1790336A4 (en) CAPSULE FILM COMPOSITION, CAPSULE FILM, AND CAPSULE COMPRISED THEREFROM
MX2008016495A (es) Maltitol granulado para compresion directa y su metodo de preparacion.
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
BR0314787A (pt) Forma de dosagem de liberação modificada
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
IL190063A (en) The history of cycloalkanes is preserved, their medicinal preparations and their uses
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
WO2006109175A3 (en) Solid dosage form of an antidiabetic drug
MXPA04003851A (es) Antipruriticos.
WO2009120844A3 (en) Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
BRPI0510820A (pt) composição farmacêutica, forma unitária de dosagem e seus usos
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину
TW200640472A (en) Solid pharmaceutical composition comprising telithromycin
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
FR2902003B1 (fr) Composition cosmetique comprenant l'ebselen, l'idebenone et autres substances actives.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2319 DE 16-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.